活化p38 MAPK激酶調控阿黴素誘發CL3 肺癌細胞凋亡之研究
碩士 === 國立清華大學 === 生物科技研究所 === 98 === Doxorubicin, also called adriamycin, is a widely used therapeutic agent in lung cancer. However, the development of drug resistance is a major problem for clinical applications of doxorubicin. Activation of the p38 mitogen-activated protein kinase (MAPK) has been...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2010
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/11356465790139468543 |